Key stats
About Virtus LifeSci Biotech Clinical Trials ETF
Home page
Inception date
Dec 16, 2014
Structure
Open-Ended Fund
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Virtus ETF Advisers LLC
Distributor
VP Distributors LLC
BBC focuses on biotech companies with lead drugs that are still in various phases of clinical trials and not yet approved marketing. Given the low historical success rates in clinical trials, the fund is a high-risk and high-reward bet on a small subset of biotech companies. It excludes companies with a lead drug candidate thats still in preclinical testing or research stage, prior to entering into human clinical trials. Also excluded are the following 12 distinct sub-industries: Animal Health, Diversified Healthcare, Investment Management, Healthcare Services, Non-Healthcare, Large Pharmaceuticals, Specialty Pharmaceuticals, Medical Devices, Vaccines, Nutraceuticals, OTC Healthcare, or Tools. As such, investors looking for broad biotech exposure, won't find it in BBC. The Index Committee utilizes various public data sources to select portfolio holdings, including, SEC filings, public documents from the U.S. FDA, company press releases and official corporate websites.
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
What's in the fund
Exposure type
Health Technology
Stocks99.02%
Health Technology97.79%
Commercial Services1.24%
Bonds, Cash & Other0.98%
Cash0.98%
Stock breakdown by region
North America87.54%
Europe11.91%
Asia0.54%
Latin America0.00%
Africa0.00%
Middle East0.00%
Oceania0.00%
Top 10 holdings
Dividends
Dividend payout history